Press Releases

You Narrowed By: 2012

Showing 1-35 of 104


2012

December

December 21

Abbott and AbbVie to Present at Financial Conferences

December 17

Abbott Announces New Testosterone Test to Measure the Hormone at Low Levels

December 17

AbbVie Inc. Common Stock Approved for Listing on NYSE Euronext Paris

December 14

Abbott Declares 356th Consecutive Quarterly Dividend

December 13

New Study Shows Promising Results For Tests That Can Help Doctors Better Evaluate Potential Heart Attacks

December 7

Abbott Announces Effectiveness of AbbVie Form 10 Registration Statement
 

November

November 28

Abbott Board of Directors Approves Separation of AbbVie and Declares Special Dividend Distribution of AbbVie Stock

November 27

Abbott’s HUMIRA® (Adalimumab) Approved in Europe for Severe Active Pediatric Crohn’s Disease

November 13

Abbott Announces Phase 3 Hepatitis C Program Details

November 12

Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

November 12

Abbott Announces Results of Analysis Exploring the Use of HUMIRA® (Adalimumab) in Simultaneously Achieving Three Key Treatment Goals for Rheumatoid Arthritis

November 10

Abbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting®

November 2

Statement: Abbott and the Abbott Fund Donate $1 Million in Funding and Products to Support Hurricane Sandy Relief Efforts
 

October

October 30

Abbott Introduces Ensure Complete™ Shakes For Adults

October 24

Abbott Announces Data Evaluating Reduction of Steroid Usage with HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis

October 24

Abbott’s ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy

October 23

Abbott Announces New Data Evaluating Mucosal Healing with HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis

October 22

Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA® (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis

October 19

Abbott Receives Positive Opinion from CHMP for HUMIRA® Use in Pediatric Crohn's Disease

October 17

Abbott Reports Double Digit Earnings Per Share Growth in the Third Quarter

October 15

Abbott's Investigational Interferon-Free Hepatitis C Treatment Regimen Achieved SVR12 (Observed Data) Rates in 99 Percent of Treatment-Naïve and 93 Percent in Prior Null Responders for Genotype 1 Patients in Phase 2b Study

October 12

Abbott Awards Two Scholarships to Inspirational Students Living with Cystic Fibrosis

October 3

Abbott Hosts Conference Call for Third-Quarter Earnings
 

September

September 28

Abbott's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Adult Patients with Moderate to Severe Ulcerative Colitis

September 25

Abbott Announces International Launch of the Absorb™ Bioresorbable Vascular Scaffold

September 21

The Journal Science Again Recognizes Abbott as One of the Top Employers in the Biotech and Pharmaceutical Industry

September 18

Abbott Named to Working Mother Magazine's 'Best Companies' List for Twelve Consecutive Years

September 13

Abbott Declares 355th Consecutive Quarterly Dividend

September 13

Abbott Recognized for Leading Citizenship Performance for Eighth Consecutive Year by Dow Jones Sustainability Indexes

September 12

According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives

September 6

Abbott to Collaborate with Astellas in CMV Vaccine Trial
 

August

August 30

Abbott's HUMIRA® (Adalimumab) Approved in Europe for Expanded Treatment of Crohn’s Disease (CD)

August 28

Abbott Announces CE Mark for Highly Sensitive Testosterone Test to Measure the Hormone at Low Levels

August 20

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

August 13

Public Voting Now Open to Help Grant Two $20,000 Abbott CFCareForward Scholarships to Students with Cystic Fibrosis